1. Home
  2. ITCI

as 07-22-2024 4:00pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Founded: N/A Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 8.2B IPO Year: N/A
Target Price: $94.83 AVG Volume (30 days): 1.6M
Analyst Decision: Strong Buy Number of Analysts: 12
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.16 EPS Growth: N/A
52 Week Low/High: $45.50 - $84.89 Next Earning Date: 08-01-2024
Revenue: $513,930,000 Revenue Growth: 65.45%
Revenue Growth (this year): 45.57% Revenue Growth (next year): 39.15%

ITCI Daily Stock ML Predictions

Stock Insider Trading Activity of Intra-Cellular Therapies Inc. (ITCI)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
RIGGS RORY B ITCI Director Jun 23 '24 Sell $75.57 4,462 $337,193.34 116,600 SEC Form 4
Hineline Lawrence J. ITCI SVP of Finance, CFO Mar 7 '24 Sell $67.12 64 $4,295.68 0 SEC Form 4
Hineline Lawrence J. ITCI SVP of Finance, CFO Mar 7 '24 Sell $66.47 4,475 $297,453.25 64 SEC Form 4
Hineline Lawrence J. ITCI SVP of Finance, CFO Mar 7 '24 Sell $67.32 29 $1,952.28 0 SEC Form 4
Hineline Lawrence J. ITCI SVP of Finance, CFO Mar 7 '24 Sell $66.54 1,100 $73,194.00 29 SEC Form 4
Hineline Lawrence J. ITCI SVP of Finance, CFO Mar 7 '24 Sell $65.28 4,453 $290,691.84 1,129 SEC Form 4
Hineline Lawrence J. ITCI SVP of Finance, CFO Mar 7 '24 Sell $66.93 6,618 $442,942.74 0 SEC Form 4
Hineline Lawrence J. ITCI SVP of Finance, CFO Mar 7 '24 Sell $66.26 6,514 $431,617.64 6,618 SEC Form 4
Neumann Mark ITCI EVP, Chief Commercial Officer Mar 7 '24 Sell $66.95 4,496 $301,007.20 29,700 SEC Form 4
Neumann Mark ITCI EVP, Chief Commercial Officer Mar 7 '24 Sell $66.37 8,636 $573,171.32 34,196 SEC Form 4
Neumann Mark ITCI EVP, Chief Commercial Officer Mar 7 '24 Sell $66.86 1,313 $87,787.18 29,700 SEC Form 4
Neumann Mark ITCI EVP, Chief Commercial Officer Mar 7 '24 Sell $65.92 1,729 $113,975.68 31,013 SEC Form 4
Neumann Mark ITCI EVP, Chief Commercial Officer Mar 7 '24 Sell $65.11 4,303 $280,168.33 32,742 SEC Form 4
Mates Sharon ITCI Chairman, President & CEO Mar 7 '24 Sell $66.38 31,958 $2,121,372.04 1,059,063 SEC Form 4
Mates Sharon ITCI Chairman, President & CEO Mar 7 '24 Sell $66.93 8,754 $585,905.22 1,050,309 SEC Form 4
Mates Sharon ITCI Chairman, President & CEO Mar 7 '24 Sell $64.80 14,541 $942,256.80 1,056,333 SEC Form 4
Mates Sharon ITCI Chairman, President & CEO Mar 7 '24 Sell $65.90 4,128 $272,035.20 1,052,205 SEC Form 4
Mates Sharon ITCI Chairman, President & CEO Mar 7 '24 Sell $66.81 1,590 $106,227.90 1,050,615 SEC Form 4
Mates Sharon ITCI Chairman, President & CEO Mar 7 '24 Sell $67.33 306 $20,602.98 1,050,309 SEC Form 4
Halstead Michael ITCI EVP and General Counsel Mar 7 '24 Sell $66.14 12,912 $853,999.68 220 SEC Form 4
Halstead Michael ITCI EVP and General Counsel Mar 7 '24 Sell $66.81 220 $14,698.20 0 SEC Form 4
Halstead Michael ITCI EVP and General Counsel Mar 7 '24 Sell $65.82 6,107 $401,962.74 1,238 SEC Form 4
Halstead Michael ITCI EVP and General Counsel Mar 7 '24 Sell $66.70 1,238 $82,574.60 0 SEC Form 4
Durgam Suresh K. ITCI EVP, Chief Medical Officer Mar 7 '24 Sell $66.34 3,728 $247,315.52 18,892 SEC Form 4
Durgam Suresh K. ITCI EVP, Chief Medical Officer Mar 7 '24 Sell $66.86 2,722 $181,992.92 16,170 SEC Form 4

Share on Social Networks: